![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Clinical Trials
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration
Antios Therapeutics, Inc. and Assembly Biosciences, Inc. announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment...
Clinical Trials
Moleculin obtains UK MHRA authorisation for Phase Ia trial of Covid-19 drug
Moleculin Biotech has obtained the UK Medicines and Healthcare Products Regulatory Agency (MHRA) authorisation to initiate a Phase Ia clinical trial of its drug,...
Clinical Trials
Symbiosis Pharmaceutical Services Starts Producing Sevuparin for Modus Future Clinical Development in Sepsis/septic shock
Modus Therapeutics Holding AB , a company developing innovative treatments for patients with high unmet medical needs, announces that Symbiosis Pharmaceutical Services Ltd (“Symbiosis”),...
Clinical Trials
Brii Bio Initiates Submission of EUA Filing to U.S. FDA for BRII-196/BRII-198, , its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients
Brii Biosciences Limited a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, announced the filing...
Clinical Trials
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Pfizer Inc. and BioNTech SE announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children...
Clinical Trials
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
Valneva SE, a specialty vaccine company, announced that it has completed recruitment of the initial cohort of elderly participants in Valneva’s Phase 3 trial,...
Clinical Trials
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
RedHill Biopharma Ltd. , a specialty biopharmaceutical company, announced preliminary top-line data from the 475-patient global Phase 2/3 study with opaganib (ABC294640) in hospitalized...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read